메뉴 건너뛰기




Volumn 12, Issue , 2016, Pages 787-797

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

Author keywords

Multidrug resistant; Resistance; UTI; lactamase

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 1B; PENICILLIN BINDING PROTEIN 1C; PENICILLIN BINDING PROTEIN 3; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG;

EID: 84970003172     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S83844     Document Type: Review
Times cited : (21)

References (48)
  • 1
    • 84870946642 scopus 로고    scopus 로고
    • Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
    • Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013; 34(1): 1-14.
    • (2013) Infect Control Hosp Epidemiol , vol.34 , Issue.1 , pp. 1-14
    • Sievert, D.M.1    Ricks, P.2    Edwards, J.R.3
  • 2
    • 84886260592 scopus 로고    scopus 로고
    • Report reveals scope of US antibiotic resistance threat
    • Hampton T. Report reveals scope of US antibiotic resistance threat. JAMA. 2013; 310(16): 1661-1663.
    • (2013) JAMA , vol.310 , Issue.16 , pp. 1661-1663
    • Hampton, T.1
  • 3
    • 84881139580 scopus 로고    scopus 로고
    • Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009
    • Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013; 34(9): 940-946.
    • (2013) Infect Control Hosp Epidemiol , vol.34 , Issue.9 , pp. 940-946
    • Zilberberg, M.D.1    Shorr, A.F.2
  • 4
    • 85027920728 scopus 로고    scopus 로고
    • Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010
    • Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis. 2013; 76(3): 379-381.
    • (2013) Diagn Microbiol Infect Dis , vol.76 , Issue.3 , pp. 379-381
    • Babinchak, T.1    Badal, R.2    Hoban, D.3
  • 5
    • 0035038698 scopus 로고    scopus 로고
    • A practical guide to antimicrobial management of complicated urinary tract infection
    • Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging. 2001; 18(4): 243-254.
    • (2001) Drugs Aging , vol.18 , Issue.4 , pp. 243-254
    • Nicolle, L.E.1
  • 6
    • 77957708554 scopus 로고    scopus 로고
    • Complicated urinary tract infections: Practical solutions for the treatment of multiresistant Gram-negative bacteria
    • Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010; 65(suppl 3): iii25-iii33.
    • (2010) J Antimicrob Chemother , vol.65 , pp. iii25-iii33
    • Pallett, A.1    Hand, K.2
  • 7
    • 84929606496 scopus 로고    scopus 로고
    • Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI)
    • Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015; 385(9981): 1949-1956.
    • (2015) Lancet , vol.385 , Issue.9981 , pp. 1949-1956
    • Wagenlehner, F.M.1    Umeh, O.2    Steenbergen, J.3    Yuan, G.4    Darouiche, R.O.5
  • 8
    • 73649114948 scopus 로고    scopus 로고
    • Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
    • Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(2): 133-164.
    • (2010) Clin Infect Dis , vol.50 , Issue.2 , pp. 133-164
    • Solomkin, J.S.1    Mazuski, J.E.2    Bradley, J.S.3
  • 9
    • 84929206762 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
    • Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015; 60(10): 1462-1471.
    • (2015) Clin Infect Dis , vol.60 , Issue.10 , pp. 1462-1471
    • Solomkin, J.1    Hershberger, E.2    Miller, B.3
  • 10
    • 84919629764 scopus 로고    scopus 로고
    • Beta-lactam/beta-lactamase inhibitor combinations: From then to now
    • Toussaint KA, Gallagher JC. Beta-lactam/beta-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015; 49(1): 86-98.
    • (2015) Ann Pharmacother , vol.49 , Issue.1 , pp. 86-98
    • Toussaint, K.A.1    Gallagher, J.C.2
  • 11
    • 77149165713 scopus 로고    scopus 로고
    • Updated functional classification of beta-lactamases
    • Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010; 54(3): 969-976.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.3 , pp. 969-976
    • Bush, K.1    Jacoby, G.A.2
  • 12
    • 84940449628 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam and ceftazidime/avibactam: Two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
    • Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015; 46(3): 266-271.
    • (2015) Int J Antimicrob Agents , vol.46 , Issue.3 , pp. 266-271
    • Liscio, J.L.1    Mahoney, M.V.2    Hirsch, E.B.3
  • 13
    • 77149179342 scopus 로고    scopus 로고
    • Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients
    • Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010; 54(3): 1213-1217.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.3 , pp. 1213-1217
    • Moya, B.1    Zamorano, L.2    Juan, C.3    Perez, J.L.4    Ge, Y.5    Oliver, A.6
  • 14
    • 0036498656 scopus 로고    scopus 로고
    • Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?
    • Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002; 34(5): 634-640.
    • (2002) Clin Infect Dis , vol.34 , Issue.5 , pp. 634-640
    • Livermore, D.M.1
  • 15
    • 77955779224 scopus 로고    scopus 로고
    • Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
    • Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10(4): 441-451.
    • (2010) Expert Rev Pharmacoecon Outcomes Res , vol.10 , Issue.4 , pp. 441-451
    • Hirsch, E.B.1    Tam, V.H.2
  • 16
    • 84945139301 scopus 로고    scopus 로고
    • Infections caused by resistant Gram-negative bacteria: Epidemiology and management
    • Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015; 35(10): 949-962.
    • (2015) Pharmacotherapy , vol.35 , Issue.10 , pp. 949-962
    • Kaye, K.S.1    Pogue, J.M.2
  • 17
    • 84896453665 scopus 로고    scopus 로고
    • Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae
    • Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014; 69(4): 871-880.
    • (2014) J Antimicrob Chemother , vol.69 , Issue.4 , pp. 871-880
    • Nguyen, H.M.1    Shier, K.L.2    Graber, C.J.3
  • 18
    • 84919640961 scopus 로고    scopus 로고
    • The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli
    • Park SH, Choi SM, Chang YK, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014; 69(10): 2848-2856.
    • (2014) J Antimicrob Chemother , vol.69 , Issue.10 , pp. 2848-2856
    • Park, S.H.1    Choi, S.M.2    Chang, Y.K.3
  • 19
    • 84555204766 scopus 로고    scopus 로고
    • Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts
    • Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012; 54(2): 167-174.
    • (2012) Clin Infect Dis , vol.54 , Issue.2 , pp. 167-174
    • Rodriguez-Bano, J.1    Navarro, M.D.2    Retamar, P.3    Picon, E.4    Pascual, A.5
  • 20
    • 84873622347 scopus 로고    scopus 로고
    • Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae
    • Hirsch EB, Guo B, Chang KT, et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis. 2013; 207(5): 786-793.
    • (2013) J Infect Dis , vol.207 , Issue.5 , pp. 786-793
    • Hirsch, E.B.1    Guo, B.2    Chang, K.T.3
  • 21
    • 77953552925 scopus 로고    scopus 로고
    • Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection
    • Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010; 65(6): 1119-1125.
    • (2010) J Antimicrob Chemother , vol.65 , Issue.6 , pp. 1119-1125
    • Hirsch, E.B.1    Tam, V.H.2
  • 22
    • 84872498847 scopus 로고    scopus 로고
    • Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes
    • van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75(2): 115-120.
    • (2013) Diagn Microbiol Infect Dis , vol.75 , Issue.2 , pp. 115-120
    • van Duin, D.1    Kaye, K.S.2    Neuner, E.A.3    Bonomo, R.A.4
  • 23
    • 84939486487 scopus 로고    scopus 로고
    • The beta-lactams strike back: Ceftazidime-avibactam
    • Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015; 35(8): 755-770.
    • (2015) Pharmacotherapy , vol.35 , Issue.8 , pp. 755-770
    • Zasowski, E.J.1    Rybak, J.M.2    Rybak, M.J.3
  • 24
    • 84908582598 scopus 로고    scopus 로고
    • Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin
    • Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014; 58(11): 6946-6948.
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.11 , pp. 6946-6948
    • Phe, K.1    Johnson, M.L.2    Palmer, H.R.3    Tam, V.H.4
  • 25
    • 84898606478 scopus 로고    scopus 로고
    • In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy
    • Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014; 58(5): 2740-2746.
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.5 , pp. 2740-2746
    • Phe, K.1    Lee, Y.2    McDaneld, P.M.3
  • 26
    • 84969942703 scopus 로고    scopus 로고
    • [webpage on the Internet]. from: Accessed February 26, 2016
    • Merck & Co., Inc. [webpage on the Internet]. Zerbaxa Prescribing Information. Available from: http: //www.zerbaxa.com/pdf/PrescribingInformation.pdf. Accessed February 26, 2016.
    • Zerbaxa Prescribing Information
  • 27
    • 84937515119 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam: A novel cephalosporin/beta-lactamase inhibitor combination
    • Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination. Pharmacotherapy. 2015; 35(7): 701-715.
    • (2015) Pharmacotherapy , vol.35 , Issue.7 , pp. 701-715
    • Cho, J.C.1    Fiorenza, M.A.2    Estrada, S.J.3
  • 28
    • 84455169919 scopus 로고    scopus 로고
    • In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms
    • Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2012; 56(1): 544-549.
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.1 , pp. 544-549
    • Bulik, C.C.1    Tessier, P.R.2    Keel, R.A.3    Sutherland, C.A.4    Nicolau, D.P.5
  • 29
    • 84875175772 scopus 로고    scopus 로고
    • In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice
    • Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 57(4): 1577-1582.
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.4 , pp. 1577-1582
    • Craig, W.A.1    Andes, D.R.2
  • 30
    • 77956123209 scopus 로고    scopus 로고
    • Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa
    • Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(9): 3933-3937.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.9 , pp. 3933-3937
    • Moya, B.1    Zamorano, L.2    Juan, C.3    Ge, Y.4    Oliver, A.5
  • 31
    • 79955536362 scopus 로고    scopus 로고
    • Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
    • Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011; 55(5): 2390-2394.
    • (2011) Antimicrob Agents Chemother , vol.55 , Issue.5 , pp. 2390-2394
    • Sader, H.S.1    Rhomberg, P.R.2    Farrell, D.J.3    Jones, R.N.4
  • 33
    • 84887449664 scopus 로고    scopus 로고
    • Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012)
    • Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother. 2013; 57(12): 6305-6310.
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.12 , pp. 6305-6310
    • Farrell, D.J.1    Flamm, R.K.2    Sader, H.S.3    Jones, R.N.4
  • 34
    • 84893465570 scopus 로고    scopus 로고
    • Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates
    • Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014; 58(2): 1218-1223.
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.2 , pp. 1218-1223
    • Snydman, D.R.1    McDermott, L.A.2    Jacobus, N.V.3
  • 35
    • 77955378731 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions
    • Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010; 54(8): 3427-3431.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.8 , pp. 3427-3431
    • Ge, Y.1    Whitehouse, M.J.2    Friedland, I.3    Talbot, G.H.4
  • 36
    • 84861121314 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses
    • Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56(6): 3086-3091.
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.6 , pp. 3086-3091
    • Miller, B.1    Hershberger, E.2    Benziger, D.3    Trinh, M.4    Friedland, I.5
  • 38
    • 84957928059 scopus 로고    scopus 로고
    • Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection
    • MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE. Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2015; 60(1): 515-521.
    • (2015) Antimicrob Agents Chemother , vol.60 , Issue.1 , pp. 515-521
    • MacGowan, A.P.1    Noel, A.R.2    Tomaselli, S.G.3    Nicholls, D.4    Bowker, K.E.5
  • 40
    • 84959868380 scopus 로고    scopus 로고
    • Noninferiority doesn’t mean not inferior
    • Spellberg B, Brass EP. Noninferiority doesn’t mean not inferior. Clin Infect Dis. 2016; 62(4): 525-526.
    • (2016) Clin Infect Dis , vol.62 , Issue.4 , pp. 525-526
    • Spellberg, B.1    Brass, E.P.2
  • 43
    • 84954153001 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
    • Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016; 56(1): 56-66.
    • (2016) J Clin Pharmacol , vol.56 , Issue.1 , pp. 56-66
    • Xiao, A.J.1    Miller, B.W.2    Huntington, J.A.3    Nicolau, D.P.4
  • 44
    • 84906085321 scopus 로고    scopus 로고
    • Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections
    • Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58(9): 5350-5357.
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.9 , pp. 5350-5357
    • Lucasti, C.1    Hershberger, E.2    Miller, B.3
  • 45
    • 84929832591 scopus 로고    scopus 로고
    • Trial of short-course antimicrobial therapy for intraabdominal infection
    • Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015; 372(21): 1996-2005.
    • (2015) N Engl J Med , vol.372 , Issue.21 , pp. 1996-2005
    • Sawyer, R.G.1    Claridge, J.A.2    Nathens, A.B.3
  • 47
    • 84878278251 scopus 로고    scopus 로고
    • 10 x ‘20 progress-development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America
    • Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 x ‘20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(12): 1685-1694.
    • (2013) Clin Infect Dis , vol.56 , Issue.12 , pp. 1685-1694
    • Boucher, H.W.1    Talbot, G.H.2    Benjamin, D.K.3
  • 48
    • 57749107808 scopus 로고    scopus 로고
    • Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America
    • Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1-12.
    • (2009) Clin Infect Dis , vol.48 , Issue.1 , pp. 1-12
    • Boucher, H.W.1    Talbot, G.H.2    Bradley, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.